BRIEF-GSK starts Phase III study to evaluate dabrafenib-trametinib combination for melanoma

LONDON Fri Feb 1, 2013 7:06am EST

Related Topics

LONDON Feb 1 (Reuters) - GlaxoSmithKline Plc : * Press release: GlaxoSmithKline starts phase iiistudy to test combined

braf/mek inhibition in patients with braf positivemelanoma following surgery * Primary endpoint of the study is relapse-free survival

FILED UNDER:
A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article